Gene, Cell and Tissue

Published by: Kowsar

Serum Levels of Interleukin-27 and Interleukin-33 in Patients With Dermatomyositis and Polymyositis Compared to Healthy Control Subjects

Gellare Shahryari 1 , Ali Shahraki 1 , * and Zahra Zakeri 2
Authors Information
1 Department of Biology, Faculty of Sciences, University of Sistan and Baluchestan, Zahedan, IR Iran
2 Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Gene, Cell and Tissue: October 01, 2015, 2 (4); e31087
  • Published Online: October 18, 2015
  • Article Type: Research Article
  • Received: June 27, 2015
  • Revised: August 10, 2015
  • Accepted: August 30, 2015
  • DOI: 10.17795/gct-31087

To Cite: Shahryari G, Shahraki A, Zakeri Z. Serum Levels of Interleukin-27 and Interleukin-33 in Patients With Dermatomyositis and Polymyositis Compared to Healthy Control Subjects, Gene Cell Tissue. 2015 ; 2(4):e31087. doi: 10.17795/gct-31087.

Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hak AE, de Paepe B, de Bleecker JL, Tak PP, de Visser M. Dermatomyositis and polymyositis: new treatment targets on the horizon. Neth J Med. 2011; 69(10): 410-21[PubMed]
  • 2. Castro C, Gourley M. Diagnosis and treatment of inflammatory myopathy: issues and management. Ther Adv Musculoskelet Dis. 2012; 4(2): 111-20[DOI][PubMed]
  • 3. Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002; 14(8): 917-24[PubMed]
  • 4. Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W, Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2012; 32(3): 639-43[DOI][PubMed]
  • 5. Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004; 173(2): 715-20[PubMed]
  • 6. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007; 25: 221-42[DOI][PubMed]
  • 7. Yoshida H, Miyazaki Y. Regulation of immune responses by interleukin-27. Immunol Rev. 2008; 226: 234-47[DOI][PubMed]
  • 8. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy. 2010; 40(2): 200-8[DOI][PubMed]
  • 9. Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009; 31(1): 5-7[DOI][PubMed]
  • 10. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol. 2011; 187(4): 1609-16[DOI][PubMed]
  • 11. Shen H, Xia L, Xiao W, Lu J. Increased levels of interleukin-27 in patients with rheumatoid arthritis. Arthritis Rheum. 2011; 63(3): 860-1[DOI][PubMed]
  • 12. Shahraki A, Zakeri Z, Hossenian M, Hajnegad S. Interleukin-33 and Interleukin-18 serum levels in patients with rheumatoid arthritis and osteoporesis. J Birjand Univ Med Sci. 2014; 21(1): 86-95
  • 13. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7): 344-7[DOI][PubMed]
  • 14. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8): 403-7[DOI][PubMed]
  • 15. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362(9388): 971-82[DOI][PubMed]
  • 16. Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S. Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med. 2008; 47(18): 1593-9[PubMed]
  • 17. Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol. 2013; 31(3): 428-32[PubMed]
  • 18. Wojno ED, Hunter CA. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 2012; 33(2): 91-7[DOI][PubMed]
  • 19. Shen H, Xia L, Lu J. Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases. Cytokine. 2012; 60(2): 334-7[DOI][PubMed]
  • 20. Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol. 2008; 180(2): 922-30[PubMed]
  • 21. Baek SH, Lee SG, Park YE, Kim GT, Kim CD, Park SY. Increased synovial expression of IL-27 by IL-17 in rheumatoid arthritis. Inflamm Res. 2012; 61(12): 1339-45[DOI][PubMed]
  • 22. Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011; 26(9): 1132-9[DOI][PubMed]
  • 23. Yuan FL, Li X, Lu WG, Li CW, Xu RS, Dong J. IL-33: a promising therapeutic target for rheumatoid arthritis? Expert Opin Ther Targets. 2011; 15(5): 529-34[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments